Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 5/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.32 |
| ▸ | BCHE | P06276 | 4/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23648065 | 0.85 | ACHE (0.32) | ACHEGRIN1GRIN2ABCHEMAPT | |
| SCHEMBL30005177 | 0.85 | ACHE (0.32) | ACHEGRIN1GRIN2ABCHEMAPT | |
| SCHEMBL21722857 | 0.78 | ACHE (0.33) | ACHEGRIN1GRIN2ABCHEMAPT | |
| SCHEMBL29284972 | 0.77 | ACHE (0.35) | ACHEGRIN1GRIN2ABCHE | |
| SCHEMBL30365888 | 0.77 | ACHE (0.35) | ACHEGRIN1GRIN2ABCHE | |
| SCHEMBL6231710 | 0.74 | ACHE (0.42) | ACHEGRIN1GRIN2ABCHEMAPT | |
| SCHEMBL26528126 | 0.73 | KDM4E (0.35) | MAPT | |
| SCHEMBL22989890 | 0.73 | SOS1 (0.31) | — | |
| SCHEMBL23691562 | 0.73 | MAPT (0.33) | MAPT | |
| SCHEMBL21729545 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400561-A1 | NOVEL SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2024-12-05 | — | — | US | disclosed |
| CN-118251393-A | Novel substituted sulfonylurea compounds as inhibitors of interleukin-1 activity | 唯久生物技术(苏州)有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-20220289766-A1 | MACROCYCLIC SULFONYLUREA DERIVATIVES USEFUL AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2022-09-15 | — | — | US | disclosed |
| EP-4013761-A1 | MACROCYCLIC SULFONYLUREA DERIVATIVES USEFUL AS NLRP3 INHIBITORS | Inflazome Limited (IE) | 2022-06-22 | — | — | EP | disclosed |
| CN-114401971-A | Macrocyclic sulfonylurea derivatives as NLRP3 inhibitors | 英夫拉索姆有限公司 | 2022-04-26 | — | — | CN | disclosed |
| WO-2021032591-A1 | MACROCYCLIC SULFONYLUREA DERIVATIVES USEFUL AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021032591-A1 | MACROCYCLIC SULFONYLUREA DERIVATIVES USEFUL AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400561-A1 | NOVEL SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | IL1B, IL1A, IL18 | KDM1A 1499/4885KDM1B 3209/4885ACHE 4166/4885 |
| US-20220289766-A1 | MACROCYCLIC SULFONYLUREA DERIVATIVES USEFUL AS NLRP3 INHIBITORS | NLRP3, NOD1, PYCARD | KDM1A 2009/4885KDM1B 2283/4885ACHE 4122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.